Siren Biotechnology

San Francisco, United States Founded: 2021 • Age: 5 yrs
Developer of gene therapies for cancer treatments

About Siren Biotechnology

Siren Biotechnology is a Healthcare company based in San Francisco (United States) founded in 2021 by Nicole K Paulk. Developer of gene therapies for cancer treatments. Siren Biotechnology has raised $19.61 million across 1 funding round. Its chief executive, as recorded, is Nicole K Paulk. Siren Biotechnology offers products and services including AAV Immuno-Gene Therapy. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.

Company details

Siren Biotechnology was founded in 2021 and is headquartered in San Francisco, United States. Focus is placed on the biotechnology sector, where gene therapies for cancer treatments are developed. AAV-based gene therapy and cytokine immunotherapy are provided to stimulate immediate anti-tumor responses across multiple indications. Operations center on advancing these therapies for clinical applications in oncology.

Key Metrics
  • Total Equity Funding
    $19.61M (USD)

    in 1 rounds

  • Latest Funding Round
    $19.61M (USD), Series B

    Apr 2024

Products & Services of Siren Biotechnology

Siren Biotechnology offers a comprehensive portfolio of products and services, including AAV Immuno-Gene Therapy.

AAV Immuno-Gene Therapy
Gene Therapy

Combines AAV vectors and cytokines to treat solid tumor cancers.

Apps and channels of Siren Biotechnology

its YouTube channel Siren Biotechnology has 36 subscribers.

Siren Biotechnology
YouTube 36 subscribers Science & Technology
Open channel

Funding Insights of Siren Biotechnology

Siren Biotechnology has successfully raised a total of $19.61M through 1 strategic funding round. The most recent funding activity was a Series B round of $19.61 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $19.61M
  • Total Rounds 1
  • Last Round Series B β€” $19.61M
  • First Round $19.61M

    (Apr 2024)

All 1 funding rounds of Siren Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2024$19.61MSeries B––
–

People of Siren Biotechnology

3 people are tracked at Siren Biotechnology (3 in leadership).

NameRoleGroup
Nicole K Paulk
Founder & CEOLeadership
Nathalie Clement 🇺🇦
VP Vector Development for Translational Gene TherapiesLeadership
Nicole K. Paulk, PhD
CEO, Founder, PresidentLeadership
Premium access

Complete people profiles for Siren Biotechnology

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Siren Biotechnology

2 dated milestones of Siren Biotechnology across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Siren Biotechnology is founded.
  2. Funding First funding round of $19.6M.

Competitors of Siren Biotechnology

Siren Biotechnology has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
incyte.com1991Wilmington, United States1,387
Small molecules are developed for cancer and skin disease treatments.
Premium access

Detailed competitors of Siren Biotechnology

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Siren Biotechnology

The website of Siren Biotechnology (sirenbiotechnology.com) receives about 3K visits a month.

  • Monthly visits
    3K

    ▼ 26.8% vs previous month

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Siren Biotechnology (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Siren Biotechnology

Premium access

Complete news archive for Siren Biotechnology

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Siren Biotechnology

Siren Biotechnology was founded in 2021 and raised its 1st funding round 3 years after it was founded.

Siren Biotechnology is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Nicole K Paulk is the CEO of Siren Biotechnology, as recorded in our data. They have also founded this company.

Siren Biotechnology is a funded company, having raised a total of $19.61M across 1 funding round to date. The company's 1st funding round was a Series B of $19.61M, raised on Apr 2024.

Siren Biotechnology was founded in 2021 and is headquartered in San Francisco, United States. Focus is placed on the biotechnology sector, where gene therapies for cancer treatments are developed. AAV-based gene therapy and cytokine immunotherapy are provided to stimulate immediate anti-tumor responses across multiple indications. Operations center on advancing these therapies for clinical applications in oncology.

Siren Biotechnology's top competitors include Moderna, BeiGene and Incyte.

Siren Biotechnology offers AAV Immuno-Gene Therapy.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available